Introduction {#Sec1}
============

Type 2 diabetes (T2D) is a chronic progressive disease and is a major public health problem worldwide. Sustained hyperglycemia, measured by glycosylated hemoglobin A1c level (HbA1c), can result in preventable complications that affect health and quality of life and are costly for health care systems \[[@CR1], [@CR2]\]. The prevalence of T2D in Asia is substantial and is increasing over time, with recent estimates suggesting that the prevalence of diabetes is 9.3% in China, 7.6% in Japan, and 7.3% in South Korea \[[@CR3]\].

Based on clinical trial results, insulin is the most effective glucose-lowering therapy and can improve quality of life by preventing hyperglycemia and reducing diabetic complications \[[@CR4], [@CR5]\]. International guidelines recommend that insulin treatment may be modified over time to achieve HbA1c targets \[[@CR6]\], which are \<7% (\<53 mmol/mol) in Japan \[[@CR7]\] and China \[[@CR8]\] and \<6.5% (\<48 mmol/mol) in South Korea \[[@CR9]\]; however, although most patients with T2D have HbA1c levels above these targets, many do not progress their insulin treatment (i.e., switch from basal to a mixed insulin regimen, add bolus doses, and/or increase dosing frequency) \[[@CR10]--[@CR12]\]. Overall, preliminary evidence suggests that various clinical and psychosocial factors prevent insulin progression at the patient, provider, and health care system levels \[[@CR13]\]. As for patients, barriers may include fear, pain, concern over weight gain and/or disease progression, and inconvenience associated with injections \[[@CR14], [@CR15]\]. For the physician and health care system, barriers may include concerns over hypoglycemia, lack of experience, lack of qualified personnel, and lack of reimbursement for medicines or services \[[@CR11], [@CR14], [@CR16]\]. Although the health burden of T2D is increasing in East Asia, only a few studies have actually examined patterns and trends of insulin progression or barriers associated with insulin treatment and its intensification in this population \[[@CR17], [@CR18]\].

The Multinational Observational Study Assessing Insulin use: understanding the challenges associated with progression of therapy (MOSAIc \[ClinicalTrials.gov identifier, NCT01400971\]) study is a 2-year, global, non-interventional, prospective, and observational cohort study designed to identify factors that influence insulin progression among patients with T2D \[[@CR19]\]. Within this study, data from MOSAIc patients from three countries, China, Japan, and South Korea, have been investigated at baseline and longitudinally over 2 years to identify patterns and trends of insulin treatment and progression as well as its associated barriers with insulin progression. Thus, this first of two articles presents the baseline demographic, clinical, treatment, and psychosocial characteristics of Japanese, Chinese, and South Korean MOSAIc patients, while cross-sectional data of treatment progression and attitudes toward therapy will be analyzed separately.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

The rationale and design of the MOSAIc study have been reported elsewhere \[[@CR13]\]. MOSAIc is a multinational, non-interventional, prospective, and observational cohort study. Patients were recruited from July 2011 to July 2013 in 18 countries. Within the East Asian analysis, study sites comprised specialist and general practice centers in urban and rural areas in Japan, China, and South Korea. Patients were observed for 2 years after study enrollment with visits approximately 6, 12, 18, and 24 months after the baseline visit, with all visits being part of the patient's normal care.

The MOSAIc protocol was approved by local review boards and all patients provided written informed consent before participation in the study. The study was conducted in accordance with the Declaration of Helsinki guidelines on good clinical practices as well as applicable laws and regulations of the countries in which the study was conducted. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Study Population {#Sec4}
----------------

Eligible study patients at screening were previously diagnosed with T2D, at least 18 years of age, presenting with T2D to a study site as part of normal medical care, and receiving any commercially available initial insulin therapy for at least 3 months, with or without any combination of approved noninsulin anti-hyperglycemic agents (AHAs) (e.g., metformin). Patients were considered ineligible if they were receiving intensive basal-bolus therapy or had initiated insulin at a dose of three injections of mixed insulin.

Baseline Data Collection and Patient-Reported Outcomes {#Sec5}
------------------------------------------------------

Patient data regarding demographic and clinical characteristics, comorbid conditions, and treatment regimens were retrospectively collected from medical records at the study site for a period of up to 6 months before the baseline visit.

Patient reported outcomes (PROs) to assess emotional distress and disease knowledge were derived from previously validated diabetes instruments, and the translated questionnaires into Asian languages went through linguistic validation. The Diabetes Distress Scale (DDS) is a 25-item survey that examines the patient relationship with the health care provider and the physician perception of the patient \[[@CR20]\]. The DDS was used to assess patient anxiety regarding the management of diabetes on a six-point Likert scale; scores ranged from 17 (no distress) to 102 (severe distress). The Brief Diabetes Knowledge Test, a nine-item test modified from the Diabetes Knowledge Test, was used to examine the patient's diabetes knowledge \[[@CR21]\]. In addition, the study team developed survey tools for MOSAIc \[[@CR13]\], including the Hypoglycemia and Fasting Survey and the Insulin Specific Adherence Questionnaire. The Hypoglycemia and Fasting Survey examined the experience of and reactions to hypoglycemia, and included a question about the frequency with which the patient has experienced hypoglycemia-related events (between "Never" and "Always \[every day\]"). The Insulin Specific Adherence Questionnaire evaluated adherence to insulin therapy and assessed patients' willingness to increase the frequency of injections.

Statistical Analysis {#Sec6}
--------------------

Baseline patient characteristics were analyzed by country by calculating the number and percentage of patients for categorical variables and the mean and standard deviation (SD) for continuous variables. Chained equation methods were used to impute missing items among independent variables \[[@CR22]\]. Statistical significance was evaluated by calculating *P* values using ANOVA for demographic measures, pooled ANOVA for clinical measures and PROs, Cochran-Mantel--Haenszel test for comorbidities, and Chi-squared test for treatment profiles. Linear regression models were used to assess the association between DDS and selected covariates (age, sex, duration of diabetes, HbA1c, body mass index \[BMI\], number of noninsulin AHAs, injection frequency, Brief Diabetes Knowledge Test score, and rate of hypoglycemia per month). All analyses were performed using SAS 9.3 (SAS Institute; Cary, NC, USA) and Stata 13 (StataCorp LP; College Station, TX, USA).

Results {#Sec7}
=======

A total of 373 patients in China, 157 in Japan, and 141 in South Korea were evaluated. Baseline demographic and clinical characteristics varied among patients in the three countries (Table [1](#Tab1){ref-type="table"}). A significantly higher proportion of female patients was observed in China (56.0%) compared with the proportions in Japan (38.9%) and South Korea (36.2%) (*P* \< 0.0001). The mean (±SD) age differed significantly between countries, with the highest age in Japan (64.3 ± 12.7 years) and the lowest in China (60.8 ± 10.2 years).Table 1Demographic and baseline clinical characteristics of patients with T2D enrolled in the MOSAIc studyVariableChina (*N* = 373)Japan (*N* = 157)South Korea (*N* = 141)*P* value, univariableDemographics Mean age, years (SD)60.8 (10.2)64.3 (12.7)62.4 (10.7)0.0028^a^ Mean duration of diabetes, years (SD)11.4 (7.5)13.8 (8.7)15.7 (8.8)\<0.0001^a^ Female, *n* (%)209 (56.0)61 (38.9)51 (36.2)\<0.0001^b^Clinical measures Mean BMI, kg/m^2^ (SD)25.1 (3.4)25.1 (5.2)25.7 (3.8)0.3139^c^ Mean most recent HbA1c, % (SD)7.6 (1.9)7.7 (1.3)8.0 (1.7)0.0538^c^ Mean most recent HbA1c, mmol/mol59.6 (20.5)60.1 (14.7)64.1 (18.2)0.0538^c^Comorbidities, *n* (%) Myocardial infarction/coronary artery disease77 (20.6)21 (13.4)26 (18.4)0.1441^b^ Congestive heart failure21 (5.6)4 (2.5)1 (0.7)0.0221^b^ Hypertension199 (53.4)86 (54.8)96 (68.1)0.0092^b^ Hyperlipidemia204 (54.7)94 (59.9)88 (62.4)0.2279^b^ Stroke18 (4.8)5 (3.2)9 (6.4)0.4319^b^ Nephropathy70 (18.8)43 (27.4)50 (35.5)0.0003^b^ Neuropathy118 (31.6)24 (15.3)56 (39.7)\<0.0001^b^ Retinopathy84 (22.5)40 (25.5)69 (48.9)\<0.0001^b^ Depression13 (3.5)5 (3.2)12 (8.5)0.0326^b^No. of AHAs, mean (SD)0.6 (0.8)1.8 (1.2)0.8 (0.7)\<0.0001^b^ Metformin, *n* (%)100 (26.8)64 (40.8)71 (50.4)\<0.0001 Sulfonylurea, *n* (%)23 (6.2)80 (51.0)26 (18.4)\<0.0001 Dipeptidyl peptidase-4 inhibitor, *n* (%)1 (0.3)70 (44.6)1 (0.7)\<0.0001 α-Glucosidase inhibitor, *n* (%)75 (20.1)31 (19.7)7 (5.0)0.0001 GLP-1, *n* (%)0 (0.0)0 (0.0)0 (0.0)NA Other medicine, *n* (%)37 (9.9)37 (23.6)13 (9.2)\<0.0001Frequency of insulin injection, injections/day, mean (SD)1.9 (0.6)1.3 (0.5)1.3 (0.5)\<0.0001^b^*AHA* anti-hyperglycemic agent, *ANOVA* analysis of variance, *BMI* body mass index, *GLP-1* glucagon-like peptide-1 receptor agonist, *HbA1c* glycosylated hemoglobin A1c level, *SD* standard deviation, *T2D* type 2 diabetes^a^ANOVA test^b^Cochran-Mantel--Haenszel test^c^Pooled ANOVA test

Similarly, the mean (±SD) duration of diabetes also differed, being longer in South Korea (15.7 ± 8.8 years) than in China (11.4 ± 7.5 years) and in Japan (13.8 ± 8.7 years) (*P* \< 0.0001).

The baseline prevalence of some comorbidities also differed between countries. Diabetes-related comorbidities, whose prevalence differed significantly, included congestive heart failure, nephropathy, neuropathy, and retinopathy (Table [1](#Tab1){ref-type="table"}). In particular, microvascular diseases (i.e., nephropathy, neuropathy, and retinopathy) were significantly more observed (≥35.5%) in South Korea than in China and Japan (*P* ≤ 0.0003).

Patient use of noninsulin AHAs, which include oral antidiabetic agents and glucagon-like peptide-1 (GLP-1) receptor agonists, differed significantly among the countries. Japanese patients used more AHAs (mean = 1.8 medicines) compared with Chinese (0.6 medicines) and South Korean (0.8 medicines) patients (Table [1](#Tab1){ref-type="table"}). Sulfonylurea and dipeptidyl peptidase-4 (DPP-4) inhibitor treatments were highest amongst Japanese patients, whereas metformin was the most commonly used AHA in China and South Korea. There was no reported GLP-1 receptor agonist use among patients at baseline. Insulin regimens also differed significantly among the countries, with Chinese patients injecting insulin more frequently than Japanese and South Korean patients (Table [1](#Tab1){ref-type="table"}). The most common insulin regimen in Japan and South Korea was once-daily basal insulin, whereas the most common regimen in China was twice-daily mixed insulin (Table [2](#Tab2){ref-type="table"}).Table 2Baseline insulin regimen and injection frequency of patients with T2D enrolled in the MOSAIc studyCategory of insulin regimenInsulin frequency (per day)China\
*n* (%)\
(*N* = 373)Japan\
*n* (%)\
(*N* = 157)South Korea\
*n* (%)\
(*N* = 141)Basal insulin onlyOverall60 (16.1)106 (67.5)79 (56.0)Once52 (86.7)99 (93.4)77 (97.5)More than once8 (13.3)7 (6.6)2 (2.5)Mixed insulin onlyOverall249 (66.8)16 (10.2)13 (9.2)Once8 (3.2)1 (6.3)2 (15.4)More than once241 (96.8)15 (93.8)11 (84.6)Short-acting insulin onlyOverall13 (3.5)13 (8.3)4 (2.8)Once0 (0.0)1 (7.7)2 (50.0)More than once13 (100.0)12 (92.3)2 (50.0)Other insulin combinationsOverall51 (13.7)17 (10.8)41 (29.1)Once16 (31.4)7 (41.2)21 (51.2)More than once35 (68.6)10 (58.8)20 (48.8)Overall regimen *P* value \<0.0001 (Chi-squared test)*T2D* type 2 diabetes

In terms of PROs, the DDS (mean ± SD) scores differed significantly across countries, with South Korean patients reporting greater DDS scores (43.3 ± 16.6) than those from China (28.1 ± 10.6) and Japan (31.5 ± 13.5) (Table [3](#Tab3){ref-type="table"}). Results from the Brief Diabetes Knowledge Test demonstrated that Chinese patients recorded the highest number of questions correctly with a mean (±SD) score of 6.82 ± 1.75 questions answered correctly (Table [3](#Tab3){ref-type="table"}). Using the Hypoglycemia and Fasting Survey, it was found that a significantly higher proportion of South Korean patients (46.8%) experienced at least 1 hypoglycemic episode per month, compared with Chinese (29.5%) and Japanese (20.4%) patients. Responses from the Insulin Specific Adherence Questionnaire demonstrated that a greater proportion of South Korean and Japanese patients (64.5% and 59.9%, respectively) was willing to increase their insulin injection frequency to control their diabetes compared with Chinese patients (29.5%), whose regimens already consisted of more frequent injections.Table 3Patient-reported outcomes in patients with T2D enrolled in the MOSAIc studyPatient-reported outcomesChina (*N* = 373)Japan (*N* = 157)South Korea (*N* = 141)*P* value, univariableDDS, mean (SD)28.1 (10.6)31.5 (13.5)43.3 (16.6)\<0.0001^a^Brief diabetes knowledge test, mean (SD)6.82 (1.75)5.59 (2.05)3.28 (1.51)\<0.0001^a^\>1 hypoglycemic episode/month, *n* (%)110 (29.5)32 (20.4)66 (46.8)\<0.0001^b^≥1 hypoglycemic episode/week, *n* (%)12 (3.2)7 (4.5)11 (7.8)0.0807^b^Willing to add more injections to control diabetes, *n* (%)110 (29.5)94 (59.9)91 (64.5)\<0.0001^b^*DDS* Diabetes Distress Scale, *SD* standard deviation, *T2D* type 2 diabetes^a^Pooled ANOVA test^b^Chi squared test

There were no notable differences among East Asian patients regarding the association between DDS and duration of diabetes, HbA1c, BMI, number of AHAs, or injection frequency (Table [4](#Tab4){ref-type="table"}). However, Chinese and South Korean patients who experienced hypoglycemia more than once per month recorded higher DDS scores compared with those who experienced hypoglycemia less frequently \[*P* = 0.036 (China); *P* = 0.021 (South Korea)\]. Higher DDS scores were also recorded by younger Japanese patients (*P* = 0.044) compared with older patients and by male South Korean patients compared with female patients (*P* = 0.037). The Brief Diabetes Knowledge Test score was inversely associated with DDS in all three countries, but this was not statistically significant.Table 4Association between baseline Diabetes Distress Score and other outcome measures in patients with T2D enrolled in the MOSAIc studyCovariablesChinaJapanSouth KoreaEstimate*P*Estimate*P*Estimate*P*Age−0.080.20−0.240.04\*−0.210.15Female sex (vs male)−1.520.18−1.910.40−6.180.04\*Duration of diabetes0.130.130.250.09−0.030.84HbA1c0.350.280.980.281.040.44BMI0.010.93−0.190.600.700.09Number of non-insulin AHAs−0.060.93−0.410.67−0.230.91Injection frequency1.060.32−2.070.373.890.16Brief diabetes knowledge test score−0.270.43−0.480.53−0.410.68Hypoglycemia (monthly)2.580.04\*−0.810.776.900.02\**AHA* anti-hyperglycemic agent, *BMI* body mass index, *HbA1c* glycosylated hemoglobin A1c level, *T2D* type 2 diabetes\* *P* ≤ 0.05

Discussion {#Sec8}
==========

This first of a two-part series reports the baseline characteristics of East Asian patients, who participated in the MOSAIc study over a 2-year period. To our knowledge, this is the first study to compare insulin treatment profiles and the impact of T2D and its treatment on patients over time across multiple countries in East Asia. The cross-sectional data presented here indicate that there are significant differences in term of demographic, clinical, treatment, and psychosocial characteristics among the MOSAIc patients who enrolled in China, Japan, and South Korea. Notably, there were significant differences in the treatment regimens selected by study physicians, in the PRO measures recorded by patients, and differences in the factors associated with diabetes-related distress. Our results suggest that both diabetes clinical practice and the patient experience of T2D differ markedly between countries in East Asia, and we expect the 2-year MOSAIc data will provide additional information.

Baseline demographic and clinical characteristics varied among the three countries. This variability may be due to differences in the timing of insulin initiation in the patient's diabetes treatment regimen or differences in treatment patterns after insulin initiation, although our country-specific results were generally similar to those in other studies \[[@CR23]--[@CR26]\].

In terms of gender, the proportion of female patients in China (56.0%) was higher than one in Japan (38.9%) and South Korea (36.2%) in our study; the gender distributions in each country were consistent with the other country-specific large observational research on insulin usage, though epidemiologically there was more male population in the whole T2D patients in each country \[[@CR27]--[@CR29]\]. Furthermore, the higher incidence of diabetes-related complications in patients in South Korea compared with those in China and Japan may be related to more severe disease, as suggested by the longer mean duration of diabetes, we observed in South Korean patients. In addition, the different levels of access to tertiary-level hospitals in the three countries may have affected the rate of detection and accounted for some of the differences in reported proportions of some diabetes-related complications.

The insulin regimens used by MOSAIc patients also differed among the three countries; markedly fewer Chinese patients were initiated on basal insulin compared with Japanese and South Korean patients. Local guidelines in China and Japan do not recommend specific insulins for initiation, and the choice of insulin relies largely on the health care provider's discretion \[[@CR26], [@CR30]\]. In South Korea, there are no treatment guidelines; however, recommendations suggest that a patient commences on basal insulin if HbA1c \<8.5% (\<69 mmol/mol) and mixed insulin if HbA1c ≥8.5% (≥69 mmol/mol) \[[@CR31]\]. Possible explanations for the infrequent use of basal insulin in China include the higher cost of this therapy compared with short-acting and mixed insulin, which may be prohibitive to patients \[[@CR32]\]; differing levels of reimbursement for insulin products, for example, short-acting insulin, premixed insulin, and Neutral Protamine Hagedorn insulin are on the Chinese National Essential Medicines list and are usually fully reimbursed by the insurance system \[[@CR33]\]; and the tendency for Chinese physicians to choose mixed insulin to manage both fasting and high postprandial plasma glucose resulting from the high-carbohydrate diets of Chinese patients \[[@CR34]\]. The 2-year MOSAIc follow-up data will provide further information as to how these differences in insulin therapy in China will affect treatment progression.

A notable result of our study is the marked difference in treatment choices made by physicians from three countries, with patients in Japan being prescribed significantly more AHAs compared with patients in China or South Korea. These results reflect the differences in reimbursement and medicine access in East Asia. Utilization of DPP-4 inhibitors also varies dramatically across the region, with nearly half of Japanese patients in our study receiving medicines from this class at baseline, compared with less than 1% of patients in China and South Korea. This trend is explained by the earlier availability and reimbursement of DPP-4 inhibitors in Japan compared to China and South Korea. Similarly, no patient in this study recorded use of a GLP-1 receptor agonist at baseline; an observation that is reflective of the fact that GLP-1 receptor agonists only recently became available in the region. As the DPP-4 inhibitor class is now reimbursed in South Korea, and the GLP-1 receptor agonist class is reimbursed in both Japan and South Korea and available in China, the use of these medicines is expected to increase in these countries, demonstrating the pivotal role access and reimbursement has in enabling patient treatment across the region \[[@CR35]\].

Differences in baseline quality of life and diabetes distress scores between patients from various countries may be explained in part by ethnic cultural differences. For example, it may explain why Japanese patients were less likely to report higher diabetes distress rates as a result of hypoglycemia compared with Chinese or South Korean patients. However, differences in treatment regimens and other factors, such as variations in the understanding of definitions of hypoglycemia, may also contribute to this finding. In contrast to other findings published in the literature \[[@CR36], [@CR37]\], our baseline data results did not reflect that patients with a higher knowledge of diabetes reported a lower DDS. The longitudinal changes in quality of life and DDS as well as any impact on insulin progression and health outcomes will be reported in the second article of this series, which will describe the findings of the 2-year East Asian MOSAIc follow-up analyses.

The extensive MOSAIc observational, real-world, self-reported data will assist in identifying patient, provider, and health care environmental factors that influence insulin regimens among T2D patients in East Asia. The data reported that in this first of a two-part series provides a baseline and introduction for the 2-year study results. In addition, although other studies have examined real-world use of insulin therapy in East Asia, the MOSAIc study provides clinical and psychosocial analyses over a longer duration of follow-up, and is specifically aimed at addressing the current lack of evidence regarding insulin progression and the barriers to achieving optimal care in East Asia. However, the study does have some limitations. Study participants were volunteered to answer the questionnaires, because patients were not collected in random sampling; therefore, socio-demographic and psychological characteristics may not represent the whole population. Patient records were only available from physicians participating in the study, which may limit the collection of the data if the study patients were treated by additional health care providers. In addition, the observational study design prevented the inclusion of data beyond routine diabetes care or the control of country-specific variables that may have limited the ability to directly compare the countries.

Conclusion {#Sec9}
==========

The MOSAIc baseline results suggest significant differences in baseline demographic, clinical, treatment, and psychosocial characteristics among Chinese, Japanese, and South Korean patients with T2D receiving insulin therapy. Physician treatment decisions differed among countries due to cultural, health care system, reimbursement, and access factors. The second part of this article series will present 2-year results from this study population and provide further insights on insulin treatment and progression and its impact on glycemic control for this East Asian population.
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